Novo Nordisk joined the many pharmaceutical companies pushing back on government-negotiated drug pricing in the United States.

Novo Nordisk focused on a unique argument in federal appeals court on Tuesday in a case that will consider the extent to ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...

Novo Nordisk is preparing to launch its blockbuster obesity drug Wegovy (injectable semaglutide) in India later this year, the company told Business Today, setting the stage for a high-stakes battle ...

A federal commission is calling for $15 billion in new financing to reinforce U.S. biotech leadership amid competition from ...

Rybelsus reduced the risk of cardiovascular-related death, heart attack, and stroke by 14% compared to a placebo over an ...

India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...